$ZNTL: Oncology MomentumZNTL broke 80 again today and is displaying a strong monthly momentum chart. IBB regaining 160 hopefully will signal at least a moderate health care push that could push ZNTL into the 90s and beyond. Good luck traders!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.53 USD
−292.19 M USD
0.00 USD
57.60 M
About Zentalis Pharmaceuticals, Inc.
Sector
Industry
CEO
Julia Marie Eastland
Website
Headquarters
San Diego
Founded
2014
FIGI
BBG00R2K8TF5
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
ZNTL Oversold.... bounce time? Looking for oversold confirmation and bounce
Oversold on all the scanners looking for a bounce back up to $42+
Potential double bottom...
Still lots of insider selling in the $50-$37 range.
Looking for a shake out and bounce.
Average Target Price 58.33
Both its technical analysis and fundamental reports look great. Both its technical analysis and fundamental reports look great. This is a perfect time to buy this stock.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ZNTL is 2.97 USD — it has decreased by −2.12% in the past 24 hours. Watch Zentalis Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Zentalis Pharmaceuticals, Inc. stocks are traded under the ticker ZNTL.
ZNTL stock has fallen by −4.31% compared to the previous week, the month change is a −18.83% fall, over the last year Zentalis Pharmaceuticals, Inc. has showed a −80.99% decrease.
We've gathered analysts' opinions on Zentalis Pharmaceuticals, Inc. future price: according to them, ZNTL price has a max estimate of 20.00 USD and a min estimate of 4.00 USD. Watch ZNTL chart and read a more detailed Zentalis Pharmaceuticals, Inc. stock forecast: see what analysts think of Zentalis Pharmaceuticals, Inc. and suggest that you do with its stocks.
ZNTL reached its all-time high on Nov 4, 2021 with the price of 87.19 USD, and its all-time low was 2.66 USD and was reached on Oct 31, 2024. View more price dynamics on ZNTL chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ZNTL stock is 2.39% volatile and has beta coefficient of 1.56. Track Zentalis Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Zentalis Pharmaceuticals, Inc. there?
Today Zentalis Pharmaceuticals, Inc. has the market capitalization of 208.09 M, it has increased by 10.46% over the last week.
Yes, you can track Zentalis Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Zentalis Pharmaceuticals, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ZNTL earnings for the last quarter are −0.56 USD per share, whereas the estimation was −0.91 USD resulting in a 38.44% surprise. The estimated earnings for the next quarter are −0.79 USD per share. See more details about Zentalis Pharmaceuticals, Inc. earnings.
Zentalis Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ZNTL net income for the last quarter is −40.16 M USD, while the quarter before that showed −88.28 M USD of net income which accounts for 54.51% change. Track more Zentalis Pharmaceuticals, Inc. financial stats to get the full picture.
No, ZNTL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 31, 2024, the company has 168.00 employees. See our rating of the largest employees — is Zentalis Pharmaceuticals, Inc. on this list?
Like other stocks, ZNTL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Zentalis Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Zentalis Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Zentalis Pharmaceuticals, Inc. stock shows the sell signal. See more of Zentalis Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.